Methoxy Polyethylene Glycol-Epoetin Beta
Brand names: Mircera · Active ingredient: Methoxy Polyethylene Glycol-Epoetin Beta
In short: Mircera is indicated for the treatment of anemia associated with chronic kidney disease (CKD) in: •adult patients on dialysis and adult patients not on dialysis. •pediatric patients 3 months to 17 years of age on dialysis or not on dialysis who are converting from another ESA after their hemoglobin
What is Methoxy Polyethylene Glycol-Epoetin Beta used for?
Mircera is indicated for the treatment of anemia associated with chronic kidney disease (CKD) in:
•adult patients on dialysis and adult patients not on dialysis.
•pediatric patients 3 months to 17 years of age on dialysis or not on dialysis who are converting from another ESA after their hemoglobin level was stabilized with an ESA.
Limitations of Use
Mircera is not indicated and is not recommended:
•In the treatment of anemia due to cancer chemotherapy .
•As a substitute for RBC transfusions in patients who require immediate correction of anemia .
Mircera has not been shown to improve symptoms, physical functioning, or health-related quality of life.
⚠ Boxed warning (FDA's strongest warning)
Chronic Kidney Disease
•
In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL.
•
No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks.
•
Use the lowest Mircera dose sufficient to reduce the need for red blood cell (RBC) transfusions.
Cancer
•
Mircera is not indicated and is not recommended for the treatment of anemia due to cancer chemotherapy. A dose-ranging study of Mircera was terminated early because of more deaths among patients receiving Mircera than another ESA.
•
ESAs have shown shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies in patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers.
Methoxy Polyethylene Glycol-Epoetin Beta dosage
Evaluation of Iron Stores and Nutritional Factors
Evaluate the iron status in all patients before and during treatment. Administer supplemental iron therapy when serum ferritin is less than 100 mcg/L or when serum transferrin saturation is less than 20%. The majority of patients with CKD will require supplemental iron during the course of ESA therapy.
Monitoring of Response to Therapy
Correct or exclude other causes of anemia (e.g., vitamin deficiency, metabolic or chronic inflammatory conditions, bleeding, etc.) before initiating Mircera . Following initiation of therapy and after each dose adjustment, monitor hemoglobin weekly until the hemoglobin level is stable and sufficient to minimize the need for RBC transfusion.
Individualization of Dosing
Individualize and use the lowest dose of Mircera sufficient to reduce the need for RBC transfusions . In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL for adult patients. No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks. Physicians and patients should weigh the possible benefits of decreasing transfusions against the increased risks of death and other serious cardiovascular adverse events .
Prefilled syringes are not designed for administration of partial doses. Round doses to the closest dose achievable with the prefilled syringes.
When initiating or adjusting therapy, monitor hemoglobin levels at least weekly until stable, then monitor at least monthly. When adjusting therapy consider hemoglobin rate of rise, rate of decline, ESA responsiveness and hemoglobin variability. A single hemoglobin excursion may not require a dosing change.
•Do not increase the dose more frequently than once every 4 weeks. Decreases in dose can occur more frequently. Avoid frequent dose adjustments.
•If the hemoglobin rises rapidly (e.g., more than 1 g/dL in any 2-week period), reduce the dose of Mircera by approximately 25% to the closest dose achievable with the prefilled syringes to reduce rapid responses.
•If the hemoglobin continues to rise following a dose reduction, discontinue Mircera until the hemoglobin level begins to decrease, at which point therapy should be restarted with a dose that is approximately 25% below the previously administered dose.
•For patients who do not respond adequately, if the hemoglobin has not increased by more than 1 g/dL after 4 weeks of therapy, increase the dose by approximately 25% to the closest dose achievable with the prefilled syringes. …
How to take Methoxy Polyethylene Glycol-Epoetin Beta — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).
Inform patients:
•Of the increased risks of mortality, serious cardiovascular reactions, thromboembolic reactions, stroke, and tumor progression .
•To undergo regular blood pressure monitoring, adhere to prescribed anti-hypertensive regimen and follow recommended dietary restrictions.
•To seek medical care immediately if they experience any symptoms of an allergic reaction with use of Mircera .
•To contact their healthcare provider for new-onset neurologic symptoms or change in seizure frequency.
•Of the need to have regular laboratory tests for hemoglobin.
Administer Mircera under the direct supervision of a healthcare provider or, in situations where a patient or caregiver has been trained to administer Mircera at home, provide instruction on the proper use of Mircera, including instructions to:
•Carefully review the Medication Guide and the Instructions for Use.
•Avoid the reuse of needles, syringes, or unused portions of the Mircera single-dose prefilled syringes and to properly dispose of these items. …
Warnings & precautions
Do not take this medicine if: Mircera is contraindicated in patients with:
•Uncontrolled hypertension
•Pure red cell aplasia (PRCA) that begins after treatment with Mircera or other erythropoietin protein drugs
•History of serious or severe allergic reactions to Mircera (e.g., anaphylactic reactions, angioedema, bronchospasm, skin rash, and urticaria) .
•In controlled clinical trials of patients with CKD comparing higher hemoglobin targets (13 to 14 g/dL) to lower targets (9 to 11.3 g/dL), ESAs increased the risk of death, myocardial infarction, stroke, congestive heart failure, thrombosis of hemodialysis vascular access, and other thromboembolic events in the higher target groups.
•Using ESAs to target a hemoglobin level of greater than 11 g/dL increases the risk of serious adverse cardiovascular reactions and has not been shown to provide additional benefit . Use caution in patients with coexistent cardiovascular disease and stroke . Patients with CKD and an insufficient hemoglobin response to ESA therapy may be at even greater risk for cardiovascular reactions and mortality than other patients. A rate of hemoglobin rise of greater than 1 g/dL over 2 weeks may contribute to these risks.
•In controlled clinical trials of patients with cancer, ESAs increased the risks for death and serious adverse cardiovascular reactions. These adverse reactions included myocardial infarction and stroke.
•In controlled clinical trials, ESAs increased the risk of death in patients undergoing coronary artery bypass graft surgery (CABG) and the risk of deep venous thrombosis (DVT) in patients undergoing orthopedic procedures. …
Methoxy Polyethylene Glycol-Epoetin Beta side effects
The following serious adverse reactions are discussed in greater detail in other sections of the labeling:
•Increased Mortality, Myocardial Infarction, Stroke, and Thromboembolism
•Increased Mortality and/or Tumor Progression in Patients with Cancer
•Hypertension
•Seizures
•Pure Red Cell Aplasia
•Serious Allergic Reactions
•Severe Cutaneous Reactions
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of Mircera cannot be directly compared to rates in the clinical trials of other drugs and may not reflect the rates observed in practice.
Adult Patients
The data described below reflect exposure to Mircera in 2737 patients, including 1451 exposed for 6 months and 1144 exposed for greater than one year. Mircera was studied primarily in active-controlled studies (n=1789 received Mircera, and n=948 received another ESA) and in long-term follow up studies. The population was 18 to 92 years of age, 58% male, and the percentage of Caucasian, Black (including African Americans), Asian and Hispanic patients were 73%, 20%, 5%, and 9%, respectively. Approximately 85% of the patients were receiving dialysis. Most patients received Mircera using dosing regimens of once every two or four weeks, administered subcutaneously or intravenously.
The most commonly reported adverse reactions in ≥10% of patients were hypertension , diarrhea, and nasopharyngitis. …
About this medicine
Methoxy polyethylene glycol-epoetin beta, is an ESA which differs from erythropoietin through formation of a chemical bond between either the N-terminal amino group or the ε-amino group of any lysine present in erythropoietin, predominantly Lys52 and Lys45, and methoxy polyethylene glycol (PEG) butanoic acid (approximately 30,000 daltons). This results in a total molecular weight of approximately 60,000 daltons. Methoxy polyethylene glycol-epoetin beta is produced in Chinese hamster ovary (CHO) cells using recombinant DNA technology.
Mircera is formulated as a sterile, preservative-free protein solution for intravenous or subcutaneous administration. Mircera (methoxy polyethylene glycol-epoetin beta) injection is supplied in prefilled syringes (30 mcg, 50 mcg, 75 mcg, 100 mcg, 120 mcg, 150 mcg, 200 mcg, or 250 mcg in 0.3 mL) and formulated in an aqueous solution containing mannitol (9 mg), methionine (0.447 mg), poloxamer 188 (0.03 mg), sodium phosphate monobasic monohydrate (0.414 mg), and sodium sulfate (1.704 mg). …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 22c56f2a-f73c-60e7-e054-00144ff88e88. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate